phase readout
saveNCT04238715: A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
COMPLETEDupdated 5mo ago
community read0 votes
Sponsor: Eisai Co., Ltd.. Phase: PHASE2. Conditions: Cholangiocarcinoma
view source ↗Data sources
last refreshed 22m ago
Found something off?
same company · ±60 days · 6
- drug expirylenvatinib mesylate: Eisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))Apr 24, 2026
- patent expirylenvatinib mesylate: Eisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))Apr 24, 2026
- approvalERIBULIN MESYLATE — FDA approvalMar 16, 2026
- approvallecanemab: LEQEMBI (LECANEMAB-IRMB) — FDA approvalJan 16, 2026
- approvallecanemab: LEQEMBI (LECANEMAB-IRMB) — FDA approvalDec 15, 2025
- approvallecanemab: LEQEMBI (LECANEMAB-IRMB) — FDA approvalDec 15, 2025
🐶 often sniffed alongside
top 8- tagOncology18 co-mentions · 2 sources
- tagInfectious Disease2 co-mentions · 2 sources
- tagBreast Cancer2 co-mentions · 2 sources
- tagColorectal Cancer2 co-mentions · 2 sources
- tagMelanoma2 co-mentions · 2 sources
- tagFGFR2 co-mentions · 1 sources
- druglenvatinib mesylate2 co-mentions · 2 sources
- druglenvatinib2 co-mentions · 2 sources
comments(0)
5-min edit window · permanent after that